Document Detail

Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI).
MedLine Citation:
PMID:  17492403     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Recent research has demonstrated that in-vivo XIIa exists in a number of different types and that treatment with tenecteplase increases the plasma concentration of XIIaA. Only limited data exist on changes in activated Factor XII (XIIa) levels following mechanical revascularisation, such as percutaneous coronary intervention (PCI). METHODS: Citrated blood samples were obtained from 31 PCI-treated patients admitted with ST-elevation myocardial infarction (STEMI) and 20 patients undergoing elective PCI. Samples were taken immediately before the invasive procedure, 30-90 min after PCI and (in patients undergoing primary PCI) 4-6 days following intervention. Additional samples were taken after angiography, just prior to the follow-on PCI procedure, in 16 of the patients undergoing elective PCI, to investigate possible effects of contrast fluid and heparin. XIIa measurements were performed using 2 ELISA assays designed to preferentially measure different types of XIIa; XIIaA and XIIaR. RESULTS: In the group undergoing primary PCI, XIIaA showed a significant increase from 68 (48-93) pM in the pre-treatment sample to 100 (75-123) pM [median and 25- and 75% percentiles] in the 30-90-min post-treatment sample (p < 0.001), returning to pre-intervention levels by day 4-6. A similar increase in XIIaA was obtained in patients undergoing elective PCI. In contrast, no significant changes in XIIaR concentration were observed. Whilst XIIaA concentrations remained unchanged in 6 non-heparinised patients undergoing elective coronary angiography, XIIaA levels rose significantly from 56 (51-75) pM to 98 (71-125) pM [median and 25- and 75% percentiles], (p < 0.01) in 10 patients after the addition of heparin. CONCLUSION: A significant short-lasting increase in specific types of XIIa (namely XIIaA) was observed following PCI. These increases are most likely induced by the concomitant treatment with heparin.
Volker Pönitz; David Pritchard; Heidi Grundt; Mai-Britt Mehus; Dennis Winston T Nilsen
Related Documents :
23612023 - Role of pre-procedural glutathione concentrations in the prediction of major adverse ca...
23337493 - Regenerative medicine approach to repair the failing heart.
24841763 - Establishing the framework to support bioartificial heart fabrication using fibrin-base...
Publication Detail:
Type:  Journal Article     Date:  2007-05-11
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  24     ISSN:  0929-5305     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-08-03     Completed Date:  2007-12-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  131-5     Citation Subset:  IM    
Department of Medicine, Stavanger University Hospital, POB 8100, 4068 Stavanger, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary*
Contrast Media / pharmacology
Coronary Angiography
Enzyme-Linked Immunosorbent Assay
Factor XII / analysis*,  drug effects
Heparin / pharmacology
Myocardial Infarction / therapy
Up-Regulation / drug effects
Reg. No./Substance:
0/Contrast Media; 9001-30-3/Factor XII; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fibrinolytic treatment in left ventricular mobile thrombi with low ejection fraction: results and fo...
Next Document:  TMEM166, a novel transmembrane protein, regulates cell autophagy and apoptosis.